GYRE THERAPEUTICS INC
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
HIBITS
The exhibits filed or furnished as part of this Quarterly Report are set forth below.
| ExhibitNumber | Exhibit Title | Form | File No. | Incorporated by reference Exhibit No. | Filing Date |
|---|---|---|---|---|---|
| 2.1(a)†# | Asset Purchase Agreement, dated as of December 26, 2022, by and among Catalyst Biosciences, Inc., GNI Group Ltd., and GNI Hong Kong Limited. | 8-K | 000-51173 | 2.1 | Dec. 27, 2022 |
| 2.1(b) | Agreement and Amendment to Asset Purchase Agreement, dated as of March 29, 2023, by and among Catalyst Biosciences, Inc., GNI Group Ltd., and GNI Hong Kong Limited. | 8-K | 000-51173 | 2.2 | Mar. 30, 2023 |
| 2.2(a)# | Business Combination Agreement, dated as of December 26, 2022, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the individuals listed on Annex A thereto and Continent Pharmaceuticals Inc. | 8-K | 000-51173 | 2.2 | Dec. 27, 2022 |
| 2.2(b) | Amendment to Business Combination Agreement, dated as of March 29, 2023, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders and Continent Pharmaceuticals Inc. | 8-K | 000-51173 | 2.1 | Mar. 30, 2023 |
| 2.2(c) | Second Amendment to Business Combination Agreement, dated as of August 30, 2023, by and among Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc. and Continent Pharmaceuticals Inc. | 8-K | 000-51173 | 2.1 | Aug. 31, 2023 |
| 3.1 | Fourth Amended and Restated Certificate of Incorporation of the Company. | S-8 | 333-133881 | 4.1 | May 8, 2006 |
| 3.2 | Certificate of Amendment to Fourth the Amended and Restated Certificate of Incorporation of the Company. | 8-K | 000-51173 | 3.1 | Aug. 20, 2015 |
| 3.3 | Second Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company. | 8-K | 000-51173 | 3.1 | Feb. 10, 2017 |
| 3.4 | Third Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company. | 8-K | 000-51173 | 3.1 | Oct. 30, 2023 |
| 3.5 | Fourth Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company. | 8-K | 000-51173 | 3.1 | June 17, 2024 |
| 3.6 | Amended and Restated Bylaws of the Company. | 8-K | 000-51173 | 3.3 | Oct. 30, 2023 |
| 3.7(a) | Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed with the Delaware Secretary of State on April 10, 2017. | 10-Q | 000-51173 | 3.1 | Aug. 3, 2017 |
| 3.7(b) | Certificate of Elimination of Series A Preferred Stock, filed with the Delaware Secretary of State on March 25, 2024. | 10-K | 000-51173 | 3.6(b) | Mar. 27, 2024 |
| 3.8(a) | Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Delaware Secretary of State on December 27, 2022. | 8-K | 000-51173 | 3.1 | Dec. 27, 2022 |
| 3.8(b) | Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock, filed with the Delaware Secretary of State on October 30, 2023. | 8-K | 000-51173 | 3.2 | Oct. 30, 2023 |
| 3.9(a) | Certificate of Designation of Preferences, Rights and Limitations of Series Y Preferred Stock, filed with the Delaware Secretary of State on June 20, 2023, with respect to the Series Y Preferred Stock. | 8-K | 000-51173 | 3.1 | June 20, 2023 |
| 3.9(b) | Certificate of Elimination of Series Y Preferred Stock, filed with the Delaware Secretary of State on August 31, 2023. | 8-K | 000-51173 | 3.1 | Aug. 31, 2023 |
| 4.1 | Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to Silicon Valley Bank on March 3, 2005. | 10-K | 000-51173 | 4.4 | Mar. 9, 2016 |
| 4.2 | Form of Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to purchasers of convertible promissory notes. | 10-K | 000-51173 | 4.6 | Mar. 9, 2016 |
| 4.3 | Form of Warrant to Purchase Series X Convertible Preferred Stock. | 8-K | 000-51173 | 4.1 | Oct. 30, 2023 |
| 31.1* | Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Certification of the Interim Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1** | Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2** | Certification of the Interim Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS* | Inline XBRL (extensible Business Reporting Language) Instance Document |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
- Filed herewith.
** Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.
† The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5).
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) the Company customarily and actually treats that information as private or confidential and (ii) the information was not material.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.